Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK3745417 With and Without Dostarlimab in Advanced Solid Tumors
NCT03843359Phase 1Terminated
- Sponsor
- GSK
- Start
- Mar 2019
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 1, open-label trial of GSK3745417 in solid tumor (2 cohorts), sponsored by GSK. Primary endpoints: Dose-limiting Toxicity up to 29 Days and Treatment-emergent Adverse Events and Serious Treatment-emergent Adverse Events up to 30.3 weeks. Started Mar 2019; status: terminated.
02
Drugs
GSK3745417
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03843359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03843359.